Alperovich A et al. Benchmark of progression-free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era. Proc ASH 2016;Abstract 2955.
Andorsky DJ et al. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). ASCO 2017;Abstract 7502.
Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014;15(4):424-35. Abstract
Bachy E et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-term results of the PRIMA study. J Clin Oncol 2019;[Epub ahead of print]. Abstract
Casulo C et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. J Clin Oncol 2015;33(23):2516-22. Abstract
Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent Non-Hodgkin’s lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018;36(22):2259-66. Abstract
Copanlisib for injection [package insert]. Whippany, NJ:Bayer HealthCare Pharmaceuticals Inc;2017.
Crawford J et al. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21(Suppl 5):248-51. Abstract
Davies A et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): A randomized, open-label, phase 3 trial. Lancet Haematol 2017;4(6):e272-82. Abstract
Dreyling M et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 2017;35(35):3898-905. Abstract
Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl 5):v83-90. Abstract
Duvelisib [package insert]. Needham, MA:Verastem Inc;2018.
Flinn IW et al. DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;[Epub ahead of print]. Abstract
Fowler NH et al. RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. ASCO 2018;Abstract 7500.
Freedman AS, Friedberg JW. Initial treatment of advanced stage (III/IV) follicular lymphoma. UpToDate 2019;v37.0. Available at https://www.uptodate.com/contents/initial-treatment-of-advanced-stage-iii-iv-follicular-lymphoma
Gopal AK et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18. Abstract
Hainsworth JD et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002;20(20):4261-7. Abstract
Hiddemann W et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol 2018;36(23):2395-404. Abstract
Idelalisib [package insert]. Foster City, CA:Gilead Sciences Inc;2018.
Kahl BS et al. Rituximab extended schedule or re-treatment trial for low–tumor burden follicular lymphoma: Eastern Cooperative Oncology Group Protocol E4402. J Clin Oncol 2014;32(28):3096-102. Abstract
Leonard JP et al. AUGMENT: A phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma. Proc ASH 2018;Abstract 445.
Marcus RE et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: Primary results of the randomized phase 3 GALLIUM study. Proc ASH 2016;Abstract 6.
Morschhauser F et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379(10):934-47. Abstract
Salles G et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase III, randomised controlled trial. Lancet 2011;377(9759):42-51. Abstract
Santoro A et al. Outcomes for patients with high-risk relapsed or refractory indolent B-cell lymphoma treated with copanlisib in the CHRONOS-1 study. Proc ASH 2018;Abstract 395.
Sehn LH et al. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. ASCO 2015;Abstract LBA8502.
Smith TJ et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015;33:3199-212. Abstract
Taverna C et al. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: Results of the randomized controlled phase III trial SAKK 35/03. J Clin Oncol 2016;34(5):495-500. Abstract
Tobinai K et al. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 2017;34(2):324-56. Abstract
US Food and Drug Administration. FDA approves obinutuzumab for previously untreated advanced follicular lymphoma [press release]. November 16, 2017. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-obinutuzumab-previously-untreated-follicular-lymphoma
US Food and Drug Administration. FDA approves lenalidomide for follicular and marginal zone lymphoma [press release]. May 28, 2019. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenalidomide-follicular-and-marginal-zone-lymphoma
US Food and Drug Administration. FDA approves rituximab plus hyaluronidase combination for treatment of FL, DLBCL and CLL [press release]. June 22, 2017. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rituximab-plus-hyaluronidase-combination-treatment-fl-dlbcl-and-cll
van Oers MHJ et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized Intergroup study. J Clin Oncol 2010;28(17):2853-8. Abstract
Vidal L et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma — Individual patient data meta-analysis. Eur J Cancer 2017;76:216-25. Abstract
Zelenetz AD et al. NCCN guidelines insights: B-cell lymphomas, version 3.2109. J Natl Compr Canc Netw 2019;17(6):650-61. Abstract
Zinzani PL et al. Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies. Proc ESMO 2018;Abstract 1006O.
Zinzani PL et al. DYNAMO: A phase II study demonstrating the clinical activity of duvelisib in patients with double-refractory follicular lymphoma. Proc EHA 2017;Abstract S777.